Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
SalioGen Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
SalioGen Therapeutics

SalioGen Therapeutics

Series B

SalioGen Therapeutics advances mammal-derived EDIT platform for potential curative non-viral gene therapy.

HQ
Cambridge, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

SalioGen Therapeutics was founded with the mission to revolutionize gene therapy through its innovative Exact DNA Integration Technology (EDIT) platform. This mammal-derived genome engineering technology aims to provide potentially curative, non-viral gene therapies. SalioGen focuses on addressing genetic disorders, with a particular emphasis on diseases that currently lack effective treatments. Their market focus includes conditions such as cystic fibrosis and various genetic vision impairments.

Notable affiliations include strategic collaborations with companies like Nanite to develop lung-targeting nanoparticles for cystic fibrosis treatment. SalioGen has presented significant data at prestigious conferences such as the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Gene & Cell Therapy (ASGCT). These achievements underscore the company's impact on advancing gene therapy technologies and its potential to transform treatment paradigms for genetic disorders.

SalioGen Therapeutics - Similar Companies

Intergalactic Therapeutics logo

Intergalactic Therapeutics

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

Code Biotherapeutics logo

Code Biotherapeutics

codebiotx.com

eGenesis logo

eGenesis

egenesisbio.com

Intellia Therapeutics logo

Intellia Therapeutics

intelliatx.com

Nanite logo

Nanite

nanitebio.com

Sionna Therapeutics logo

Sionna Therapeutics

sionnatx.com

Editas Medicine logo

Editas Medicine

Oculogenex logo

Oculogenex

oculogenex.com

Nvelop Therapeutics logo

Nvelop Therapeutics

GenEdit logo

GenEdit

genedit.com

Xalud Therapeutics logo

Xalud Therapeutics

xaludthera.com

Ensoma logo

Ensoma

Excision BioTherapeutics logo

Excision BioTherapeutics

Aavogen logo

Aavogen

aavogen.com

SalioGen Therapeutics - Quick Facts

Who are SalioGen Therapeutics' competitors?

Companies similar to SalioGen Therapeutics include Intergalactic Therapeutics, Exegenesis Bio, Code Biotherapeutics and eGenesis.

When was SalioGen Therapeutics founded?

SalioGen Therapeutics was founded in 2020.

Where is SalioGen Therapeutics' headquarters located?

SalioGen Therapeutics' headquarters is located in Cambridge, MA, US.

When was SalioGen Therapeutics' last funding round?

SalioGen Therapeutics' most recent funding round was for $115M (USD) in January 2022.

How much has SalioGen Therapeutics raised to-date?

As of Jan 5, 2022, SalioGen Therapeutics has raised a total of $135M (USD).

How many employees does SalioGen Therapeutics have?

SalioGen Therapeutics has 91 employees as of Feb 5, 2024.

SalioGen Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Genome Engineering
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapy
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified